Sobi to acquire Arthrosi Therapeutics for $1.5bn.

Sobi, an international biopharmaceutical company, agreed to acquire Arthrosi Therapeutics, a private late-stage biotechnology company focused on developing a next-generation treatment for gout, for $1.5bn. "We are thrilled to join forces with Sobi and look forward to working together to ensure a seamless transition as they advance pozdeutinurad towards pivotal data and potential regulatory filings. We believe that Sobi’s global expertise in commercialisation will accelerate our shared mission to deliver pozdeutinurad’s potentially transformative benefits for individuals living with gout," Litain Yeh, Arthrosi Therapeutics Founder and CEO.